We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-12.34%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$111M
AUM Growth
+$65.4M
Cap. Flow
+$21.2M
Cap. Flow %
19.2%
Top 10 Hldgs %
96.91%
Holding
38
New
10
Increased
9
Reduced
4
Closed
15

Sector Composition

Rank Sector Weight
1 Miscellaneous 93%
2 Technology 3.17%
3 Healthcare 2.02%
4 Consumer Staples 1.27%
5 Utilities 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$54.1M 48.99%
725
+278
+62% +$202K
SPY icon
2
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$15.3M 13.85%
+205
New +$149K
OEF icon
3
CALL
iShares S&P 100 ETF
OEF
$20.5B
$13.3M 12.02%
+442
New +$158K
OEF icon
4
PUT
iShares S&P 100 ETF
OEF
$20.5B
$13.2M 11.99%
441
+141
+47% +$50.5K
SPY icon
5
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$4.11M 3.72%
5,500
+2,766
+101% +$2.01M
TOYO
6
TOYO Co
TOYO
$193M
$3.5M 3.17%
+503,846
New +$6.19M
ABVX
7
CALL
Abivax
ABVX
$9.89B
$1.09M 0.99%
82
+5
+6% +$566
FAMI icon
8
Farmmi Inc
FAMI
$3.91M
$840K 0.76%
+3,515,929
New +$4.28M
SIDU icon
9
PUT
Sidus Space
SIDU
$224M
$816K 0.74%
2,905
+1,856
+177% +$7.11K
CRVO icon
10
CervoMed
CRVO
$39.3M
$772K 0.7%
+248,880
New +$877K
ZVRA icon
11
PUT
Zevra Therapeutics
ZVRA
$686M
$612K 0.55%
427
+87
+26% +$967
TPST icon
12
Tempest Therapeutics
TPST
$17.5M
$568K 0.51%
511,286
+493,430
+2,763% +$814K
PAVS icon
13
Paranovus Entertainment Technology
PAVS
$4.14M
$561K 0.51%
+75,440
New +$8.07M
BIAF icon
14
bioAffinity Technologies
BIAF
$2.88M
$297K 0.27%
+24,376
New +$747K
CREG
15
DELISTED
Smart Powerr
CREG
$263K 0.24%
+127,774
New +$541K
BCTX
16
Briacell Therapeutics
BCTX
$32.5M
$262K 0.24%
80,721
+6,806
+9% +$25.1K
REVB icon
17
Revelation Biosciences
REVB
$4.18M
$217K 0.2%
210,582
+111,150
+112% +$121K
SNES icon
18
SenesTech
SNES
$5.86M
$211K 0.19%
141,756
-76,777
-35% -$125K
BCTXL
19
BriaCell Therapeutics Warrant
BCTXL
$2.67M
$169K 0.15%
190,383
-190,303
-50% -$176K
SIDU icon
20
Sidus Space
SIDU
$224M
$122K 0.11%
+43,377
New +$166K
INM icon
21
InMed Pharmaceuticals
INM
$7.37M
$69.7K 0.06%
44,970
-175,290
-80% -$194K
NUWE icon
22
Nuwellis
NUWE
$2.82M
$49.9K 0.05%
+16,372
New +$447K
BCTXZ
23
BriaCell Therapeutics Corp Warrant
BCTXZ
$315K
$11.5K 0.01%
120,802
-85,951
-42% -$8.36K
BNBX
24
DELISTED
BNB PLUS CORP
BNBX
-13,541
Closed -$8.67K
BDRX
25
Biodexa Pharmaceuticals
BDRX
$893K
-51,494
Closed -$159K

Similar funds

Sabby Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sabby Management held 38 positions worth $111M, up 145% from $45.1M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Sabby Management deployed $21.2M of net new capital in Q2 2026, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Paranovus Entertainment Technology: 75,440 shares worth $561K.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 92% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was InMed Pharmaceuticals, an estimated $194K trimmed.

  • Sabby Management's largest Q2 2026 buy was Paranovus Entertainment Technology: 75,440 shares worth $561K.
  • Sabby Management added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $2.01M increase.
  • Sabby Management's biggest Q2 2026 reduction was InMed Pharmaceuticals, cutting an estimated $194K.
  • Sabby Management fully exited Alpha Compute in Q2 2026, selling an estimated $655K.
  • Sabby Management's ten largest holdings make up 97% of its $111M portfolio in Q2 2026.
  • Sabby Management opened 10 new positions and closed 15 in Q2 2026.
  • Sabby Management's portfolio value rose 145% quarter-over-quarter to $111M.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.